Hemato-oncologists have the opportunity to obtain early indications of the possible development of AL amyloidosis by regularly determining cardiac and renal biomarkers (NT-proBNP, albuminuria) when observing patients with monoclonal gammopathies, especially those with supposedly lacking clinical significance. This evidence concerns the gene NPPB and AL amyloidosis.